Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Camrelizumab Plus Chemotherapy in PD-L1-negative Locally Advanced Cervical Cancer
NCT06288360Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Tongji Hospital. Primary endpoint: Pathologic Complete Response up to 2 years. Started Sep 2024; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06288360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06288360.